|
市場調查報告書
成人 ADHD 治療
Adult ADHD - Strattera Grows Up
|
本報告已在2011年07月19日停止出版。
有鑑於成人 ADHD（注意力缺陷過動症）患者人數是幼童患者的兩倍以上，各製藥商都把眼光集中到這個日益擴大的市場上。其中禮來（Lilly）針對 ADHD 生產的第一種治療藥物 Strattera ，預計到 2006 年會有顯著的成長。因此，其他製藥商勢必要研發出不同的商品以求做到差別化。擅長多領域市場調查分析的英國專業市調公司 Datamontor Corporation（總公司：倫敦）， 調查分析成人 ADHD ，並出版總結報告書 "Adult ADHD - Strattera Grows Up"。
該報告書包含成人 ADHD 的定義、診斷標準、患者人數、診斷情形，以及刺激藥、非刺激藥、抗憂鬱劑、未核准藥品之治療藥物及藥物生產線等，內容概編如下。
摘要
ADHD 概要
- ADHD定義
- ADHD 的病因學
- ADHD 的DSM-IV診斷標準
- 幼兒 ADHD 至成人 ADHD 的症狀推演
- 流行病學
- 成人 ADHD 的患者數量
- 成人 ADHD 的劃分
診斷
治療
- 治療指南
- 藥物療法
- 刺激藥物
- 成人 ADHD 患者使用人數
- Adderall XR（Adderall 治療 ADHD 的臨床資料、效果預測及可能性）
- Concerta（效果預測）
- J&J 及 Concerta 的可能性
- 非刺激藥物
- Strattera（Strattera 治療 ADHD 的臨床資料、效果預測及可能性）
- 抗憂鬱劑
- 未核准藥品
藥物生產線分析
- 被忽略的需求
- 生產線上的藥物
- 成人 ADHD 市場的阻力
附錄
Introduction
With the recent medical classification of adult ADHD and potentially twice
the number of patients compared to pediatric ADHD, manufacturers are seeking new
indications in this expanding and lucrative market. Lilly's Strattera was the
first drug to exploit this, and is forecast to reach blockbuster status by 2006.
Consequently, manufacturers will need to differentiate their products from
Strattera.
Scope
- Overview of the epidemiology of adult ADHD, with an assessment of the
untapped patient potential
- Discussion of the problems facing physicians in the diagnosis of adult
ADHD
- Analysis of the current market leaders and primary contenders for market
entry, with adult ADHD-specific market forecasts
- Exploration of product positioning and life-cycle management strategies
currently used by Strattera, Adderall XR and Concerta
Report Highlights
Strattera was the first drug approved for the treatment of adult ADHD in
November 2002. Since launch Strattera has a steady sales increase from $55m in
Q1 2003 to $133m in Q4 2003, and Datamonitor has forecast Strattera to reach
blockbuster status by 2006.
Shire's Adderall XR recently received an approvable letter from the FDA for
adult ADHD and J&J's Concerta is currently in Phase III with an expected
launch in 2005. Datamonitor forecasts that both drugs will see an increase in
sales from gaining an indication for this market, although both will also
experience a decline in revenues post 2005.
Approximately 75% of adults with ADHD present with a comorbid condition, of
which anxiety and depressive disorders predominate. Datamonitor has highlighted
two drug classes, which may benefit from further investigation of the treatment
of such comorbidities in order to increase their market share in the adult ADHD
market.
Reasons to Purchase
- Analyze the commercial viability of the adult ADHD market, based on
estimated patient numbers
- Develop market entry and consolidation strategies through an understanding
of key unmet needs in the market
- Identify and assess novel R&D compounds in the adult ADHD pipeline
Table of Contents
EXECUTIVE SUMMARY
- Introduction
- Scope and coverage of the Brief
- Key findings about the the topic
- Strattera was the first drug approved for the treatment of adult ADHD in
November 2002. Since launch, Strattera sales have steadily increased from
$55m in Q1 2003 to $133m in Q4 2003, and Datamonitor expects Strattera to
reach blockbuster status by 2006.
- Shire's Adderall XR recently received an approvable letter from the FDA
for an indication in adult ADHD and J&J's Concerta is currently in Phase
III with an expected launch in 2005. Datamonitor forecasts that both drugs
will see an increase in sales from gaining an indication for this market
although both will also experience a decline in revenues post 2005.
- It is currently estimated that approximately 75% of adults with ADHD
present with a comorbid condition, of which anxiety and depressive disorders
predominate. Datamonitor has highlighted two drug classes that may benefit
from further investigation of the treatment of such comorbidities in order
to increase their market share in the adult ADHD market.
DISEASE OVERVIEW
- Disease definition
- Etiology of ADHD
- Structural abnormalities
- Genetic predisposition
- Neurotransmitter dysfunction
- Dopaminergic genes
- DSM-IV diagnostic criteria of ADHD
- Progression of symptoms from pediatric to adult ADHD
- Epidemiology
- Prevalence of adult ADHD
- Segmentation of adult ADHD
- Gender
- Comorbidities
- Anxiety and mood comorbidities
- Substance abuse
DIAGNOSIS
- Diagnostic guidelines
- History of symptoms
- Diagnostic rate
TREATMENT
- Treatment guidelines
- Pharmacological treatment
- Stimulants
- Stimulants for adult ADHD
- Adderall XR
- The clinical data supporting Adderall for the treatment of adult ADHD
- Adderall XR forecast
- Opportunities for Shire and Adderall XR
- Concerta
- Concerta forecast
- Opportunities for J&J and Concerta
- Non-stimulants
- Strattera
- The clinical data supporting Strattera for the treatment of adult ADHD
- Strattera forecast
- Opportunuities for Lilly and Strattera
- Antidepressants
- Off-label prescribing
PIPELINE ANALYSIS
- Unmet needs
- Pipeline drugs
- Methypatch
- SPD-503
- Backlash to adult ADHD?
APPENDIX
- Bibliography
- Websites
- Research methodology
- Disclaimer
List of Tables
- Table 1: Symptoms of ADHD in children and adults.
- Table 2: Comorbid disorders with ADHD
- Table 3: ADHD diagnostic tools
- Table 4: Stimulants for ADHD
- Table 5: Adderall sales forecast to 2008
- Table 6: Concerta sales forecast to 2008
- Table 7: Non-stimulants for ADHD
- Table 8: Strattera sales forecast to 2008
- Table 9: Forecast sales for ADHD drugs approved for both child and adult
markets, 2002-08
- Table 10: Late stage pipeline ADHD drugs, 2004
List of Figures
- Figure 1: Prevalence of adults with ADHD in the general population across
the seven major markets, 2004
- Figure 2: Assessment of adults presenting with symptoms of ADHD
- Figure 3: Diagnosis rate of ADHD across the seven major markets, 2004
- Figure 4: ADHD pharmacological treatment algorithm
- Figure 5: ADHD patients receiving pharmacological treatment, 2004
- Figure 6: Adderall study for adult ADHD
- Figure 7: Adderall XR study in adult ADHD
- Figure 8: Adderall sales forecast to 2008
- Figure 9: Release rate of Concerta and resulting serum levels
- Figure 10: Concerta sales forecast to 2008
- Figure 11: Strattera sales forecast to 2008
- Figure 12: Sales of ADHD drugs ($m), Q3 2000(Q2 2003
- Figure 13: Methypatch sales forecast to 2008
- Figure 14: Lilly's Adult Self-Report Scale
|
